While a small sampling, BIO's third diversity report provides 'benchmark' for data-focused industry to further analyze

Kyle LaHucik

Senior Reporter

The numbers are somewhat in and biotech diversity looks relatively similar to what it has been for years.

A 2021 sampling paints a very limited picture of the industry, with BIO’s third annual diversity report including only 99 respondent companies. Most questions were not or could not be answered by every single organization, meaning many went unanswered, such as insight on board-level demographics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

While a small sampling, BIO's third diversity report provides 'benchmark' for data-focused industry to further analyze

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

AbbVie makes second deal in a week, betting $8.7B in cash on CNS biotech Cerevel

Pfizer plans to pull out of BIO, following moves by other large drugmakers to reduce lobbying footprint

Aviv Regev leads Genentech's next revolution with AI

FDA approves Novartis drug for rare blood disorder

FDA sends letter to Novartis over Kymriah manufacturing safety concerns

Early prediction of outcomes in DLBCL clinical trials through MRD testing

While a small sam­pling, BIO's third di­ver­si­ty re­port pro­vides 'bench­mark' for da­ta-fo­cused in­dus­try to fur­ther an­a­lyze

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Ab­b­Vie makes sec­ond deal in a week, bet­ting $8.7B in cash on CNS biotech Cerev­el

Pfiz­er plans to pull out of BIO, fol­low­ing moves by oth­er large drug­mak­ers to re­duce lob­by­ing foot­print

Aviv Regev leads Genen­tech's next rev­o­lu­tion with AI

FDA ap­proves No­var­tis drug for rare blood dis­or­der

FDA sends let­ter to No­var­tis over Kym­ri­ah man­u­fac­tur­ing safe­ty con­cerns

Ear­ly pre­dic­tion of out­comes in DL­B­CL clin­i­cal tri­als through MRD test­ing

While a small sampling, BIO's third diversity report provides 'benchmark' for data-focused industry to further analyze

AbbVie makes second deal in a week, betting $8.7B in cash on CNS biotech Cerevel

Pfizer plans to pull out of BIO, following moves by other large drugmakers to reduce lobbying footprint

Aviv Regev leads Genentech's next revolution with AI

FDA approves Novartis drug for rare blood disorder

FDA sends letter to Novartis over Kymriah manufacturing safety concerns

Early prediction of outcomes in DLBCL clinical trials through MRD testing